Table 1

Demographics and baseline characteristics

Study participants (N=123)
NPer cent
Sex, female7460.2
 Caucasian 114 92.7
 Pacific Islander10.8
 Delta F508 homozygous6754.5
 Delta F508 heterozygous4536.6
 Other/unknown/not genotyped118.9
Pancreatic insufficient*11795.1
Age group (years)
 10–17 4335.0
 ≥18 8065.0
FEV1% predicted†
FEV1 drop ≥10% predicted presenting for PEx‡6653.7
Intravenous antibiotic for PEx in 6 months prior§5141.5
Pseudomonas aeruginosa7964.2
Burkolderia cepacia43.3
Stenotrophomonas maltophilia1512.2
Achromobacter xylosoxidans118.9
Haemophilus influenza43.3
CF-related diabetes3730.1
Age (years)23.110.2
Body mass index (kg/m2)19.93.4
FEV1% predicted at enrolment†55.820.9
FEV1% best in 6 months prior to visit 1**63.723.9
  • *Evidence of pancreatic enzyme use.

  • †Spirometry % predicted is calculated using the Wang equations24 for females <16 years of age and males <18 years of age. The Hankinson equations23 are used for females 16 years and older, males 18 years and older.

  • ‡As reported as criterion on pulmonary exacerbation diagnostic form.

  • §One or more episodes of intravenous antibiotic for reason ‘pulmonary exacerbation’ recorded in the CFF Registry in 6 months prior to study PEx.

  • ¶Among respiratory cultures isolated at time of enrolment (n=107) or in CFF registry in 6 months prior to enrolment (n=16).

  • **Best of all spirometry in CFF Registry in 6 months prior to study PEx.

  • CF, cystic fibrosis; CFF, CF Foundation; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; PEx, pulmonary exacerbation.